Infectiologic differential diagnosis of chronic Lyme disease and so ...

More documents

Recommendations

Info

patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 2005; 53(4): 613-7. [226] Kvien TK, Gaston JS, Bardin T et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 2004; 63(9): 1113-9. [227] Yli-Kerttula T, Luukkainen R, Yli-Kerttula U et al. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003; 62(9): 880-4. [228] Lauhio A, Leirisalo-Repo M, Lähdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 34(1): 6-14. [229] Yli-Kerttula T, Luukkainen R, Yli-Kerttula U et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000; 59(7): 565-70. [230] Laasila N, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003; 62(7): 655-8. [231] Putschky N, Pott HG, Kuipers JG, Zeidler H, Hammer M, Wollenhaupt J. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann Rheum Dis, 2006; 65(11): 1521-4 [232] Fournier PE, Mainardi JL, Raoult D. Value of microimmunofluorescence for diagnosis and follow-up of Bartonella endocarditis. Clin Diagn Lab Immunol 2002; 9(4): 795-801. [233] Kerkhoff FT, Rothova A. Bartonella henselae associated uveitis and HLA-B27. Br J Ophthalmol 2000; 84(10): 1125-9. 84
[234] Carter JD, Espinoza LR, Inman RD et al. Combination antibiotics as a treatment for chronic Chlamydia- induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010; 62(5): 1298-307. [235] Gérard HC, Whittum-Hudson JA, Carter JD, Hudson AP. Molecular biology of infectious agents in chronic arthritis. Rheum Dis Clin North Am 2009; 35(1): 1- 19. [236] Carter JD, Gérard HC, Espinoza LR et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 2009; 60(5): 1311-6. [237] Fainardi E, Castellazzi M, Tamborino C et al. Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. J Neurovirol 2009; 15(5-6): 425-33. [238] Appelt DM, Roupas MR, Way DS et al. Inhibition of apoptosis in neuronal cells infected with Chlamydophila (Chlamydia) pneumoniae. BMC Neurosci 2008; 9: 13. [239] Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler 2004; 10(4): 360-9. [240] Gerard HC, Wang Z, Whittum-Hudson JA et al. Cytokine and chemokine mRNA produced in synovial tissue chronically infected with Chlamydia trachomatis and C. pneumoniae. J Rheumatol 2002; 29(9): 1827-35. [241] De Backer J, Mak R, De Bacquer D et al. Parameters of inflammation and infection in a community based case-control study of coronary heart disease. Atherosclerosis 2002; 160(2): 457-63. 85
Page 1 and 2:
Infectiologic differential diagnosi
Page 3 and 4:
3 Anamnistically, one has to consid
Page 5 and 6:
Table 2 LD coinfections (not tick-b
Page 7 and 8:
Table 5 Bartonellosis’ infection
Page 9 and 10:
Table 6 Main disease manifestations
Page 11 and 12:
11 Fig. 1. Erythrocytes infected wi
Page 13 and 14:
13 Bartonellae are localized in ery
Page 15 and 16:
ESR und CRP elevated Hypercalcemia
Page 18 and 19:
Table 9 Antibiotic treatment of bar
Page 20 and 21:
antibiosis is that the antibiotic i
Page 22 and 23:
The laboratory diagnostics for Chla
Page 24 and 25:
The arthritis occurs in 1% of the u
Page 26 and 27:
In the differential diagnosis of Ly
Page 28 and 29:
Late phase: - Reactive arthritis -
Page 30 and 31:
the depiction of chronic yersiniosi
Page 32 and 33:
In Yersinia-PCR-positive patients,
Page 34 and 35: - Incubation period 3 weeks - Atypi
Page 36 and 37: system, of the skin and other organ
Page 38 and 39: - Ehrlichia chaffeensis [1] - Anapl
Page 40 and 41: Since seroprevalence merely express
Page 42 and 43: B. microti is the predominant patho
Page 44 and 45: epresent a major health hazard and
Page 46 and 47: The decisive diagnostic information
Page 48 and 49: Probable: IFA IgG 1:1024 and one of
Page 50 and 51: The main manifestation of the Campy
Page 52 and 53: The term “reactive arthritis” i
Page 54 and 55: In the diagnosis of a “reactive a
Page 56 and 57: Table 27 Disease manifestations of
Page 58 and 59: addition, other pathogens discussed
Page 60 and 61: [8] Schouls LM, Van De Pol I, Rijpk
Page 62 and 63: [25] Hermanowska-Szpakowicz T, Skot
Page 64 and 65: [43] Bakken JS, Krueth JK, Lund T,
Page 66 and 67: [60] Fox LM, Wingerter S, Ahmed A e
Page 68 and 69: [80] Marra CM. Neurologic complicat
Page 70 and 71: [100] Pulliainen AT, Dehio C. Barto
Page 72 and 73: [118] Bass JW, Freitas BC, Freitas
Page 74 and 75: [137] Gaydos CA, Roblin PM, Hammers
Page 76 and 77: [155] Cover TL, Aber RC. Yersinia e
Page 78 and 79: multi-organ donors for the presence
Page 80 and 81: [190] Straubinger RK, Straubinger A
Page 82 and 83: [208] Bitnun A, Ford-Jones E, Blase
Page 86 and 87: [242] Appelbaum PC, Gillespie SH, B
Page 88 and 89: pneumoniae infection associated wit
Page 90 and 91: [276] Thomas NH, Collins JE, Robb S
Page 92 and 93: [294] File TM Jr, Segreti J, Dunbar
Page 94 and 95: [310] Sorvillo FJ, Lieb LE, Waterma
Page 96 and 97: henselae Isolates Collected from Ca
Page 98 and 99: [345] Raoult D, Levy PY, Harlé JR,
show all

Infectiologic differential diagnosis of chronic Lyme disease and so ...

Create successful ePaper yourself

Delete template?

Save as template?